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ABSTRACT 
Human Cytochrome P450 enzymes (CYPs) are among the most important drug metabolizing enzymes 
in the human body. They perform essential reaction steps in various biosyntheses and are thus of 
special interest for both medical and pharmaceutical research. The content of this work can be 
divided into a biotechnological section concerning drug-metabolite production and a more clinically 
related one concerning the development of fission-yeast based test systems for substrate and 
inhibitor testing. The recombinant expression of human CYPs in host organisms has been shown in 
many cases but still is a challenging task, as they are membrane-bound and need reaction partners 
and cofactors for their activities. Fission yeast is a relatively sturdy eukaryotic organism which has 
already been successfully used for the functional expression of human CYPs. The subfamily CYP3A 
accounts for both the hydroxylation of endogenous substances - predominantly steroids - and the 
conversion of about 50 % of administered drugs. During embryonic development, the expression of 
CYP3A enzymes shifts from CYP3A7, which is the most important CYP in fetal liver, to CYP3A4 which 
becomes the predominant CYP3A within the first year. During the author’s diploma thesis, the basis 
for the construction of a miniaturized test system was laid with the cloning of CYP3A7 expressing 
fission yeast cells. During the present work, the whole-cell assay with fission yeast expressing human 
CYP3A7 was established and used to investigate the metabolisation of the anti-cancer drug 
sorafenib; in addition, an inhibitor test system for CYP3A7 was developed. Furthermore, a CYP3A5 
expressing test system was established and all three human CYP3A (4, 5 and 7) enzymes were 
engineered to improve biotransformation activity for biotechnological metabolite production in a 
novel approach combining rational design and evolutionary approaches. For a further elevation of 
the biotransformation activity, three different P450 reductases were successfully tested as electron 
donors with a panel of seven human CYPs expressed in fission yeast, and interesting data concerning 
role of the reductases in the biotransformation process were gained. In addition, CYP2C9 dependent 
whole-cell biotransformation was improved to yield up to gram amounts of CYP2C9 dependent 
metabolites with 1 L batch cultures and a rare metabolite of ibuprofen was efficiently purified for the 
first time. 
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ZUSAMMENFASSUNG 
Die Familie der menschlichen Zytochrome P450 (CYPs) gehört zu den wichtigsten Enzymklassen, die 
den Medikamentenmetabolismus im menschlichen Körper katalysieren. Sie sind für vielzählige 
Reaktionsschritte in verschiedenen Biosynthesewegen verantwortlich und daher sowohl für die 
medizinische, als auch für die pharmazeutische Forschung von besonderem Interesse. Der Inhalt 
dieser Arbeit kann in einen biotechnologischen Teil bezüglich der Produktion von 
Fremdstoffmetaboliten und einen Teil mit Klinikbezug, welcher sich mit der Entwicklung eines 
spalthefebasierten Testsystems für Substrat- und Inhibitor-Tests befasst, unterteilt werden. Die 
rekombinante Expression menschlicher CYPs in Wirtsorganismen wurde vielfach gezeigt, bleibt 
jedoch eine anspruchsvolle Aufgabe, da CYPs membrangebundene Enzyme sind und verschiedene 
Reaktionspartner für Ihre Aktivität benötigen. Die Spalthefe (Schizosaccharomyces pombe) ist ein 
relativ robuster eukaryotischer Mikroorganismus, der bereits früher erfolgreich für die funktionelle 
Expression menschlicher CYPs eingesetzt wurde. Der Unterfamilie CYP3A wird sowohl die Produktion 
endogener Substanzen -vornehmlich Steroide- als auch etwa die Hälfte des gesamten 
Fremdstoffmetabolismus der Leber zugeschrieben. Während der menschlichen Entwicklung im 
Mutterleib und innerhalb des ersten Jahres nach der Geburt verschiebt sich die Expression der CYP3A 
Familie in der Leber von CYP3A7, welches das wichtigste CYP in der fötalen Leber ist, hin zu CYP3A4. 
Während der Diplomarbeit der Autorin wurde mit der Klonierung eines CYP3A7 exprimierenden 
Spalthefestamms die Grundlage für die Entwicklung eines miniaturisierten Testsystems geschaffen. 
Während der vorliegenden Arbeit wurde der Ganzzellassay mit Spalthefezellen, welche funktional 
humanes CYP3A7 eximieren, etabliert und für die Untersuchung des CYP3A7-abhängigen 
Metabolismus des Krebsmedikaments Sorafenib verwendet; zusätzlich wurde ein Inhibitor-
Testsystem für CYP3A7 spezifische Inhibitoren entwickelt. Auch ein CYP3A5 exprimierender 
Spalthefestamm wurde kloniert und alle drei humanen CYP3A Isoformen (CYP3A4, -5 und -7) wurden 
in einem innovativen Verfahren, welches den rationalen und den evolutionären Ansatz zur 
Mutagenese vereint, zur Erhöhung der Biotransformations-Aktivtäten bei der Produktion von 
Metaboliten  verbessert. Zur weiteren Verbesserung der Aktivitäten wurden erfolgreich drei 
verschiedene P450 Reduktasen als Elektronendonoren  mit einer Auswahl von sieben humanen CYPs 
getestet und so interessante Daten bezüglich der Rolle der Reduktase beim 
Biotransformationsprozess gewonnen. Zudem konnte die CYP2C9 abhängige Biotransformation mit 
ganzen Zellen optimiert werden, wodurch die Metabolitenproduktion im 1L Batch-Verfahren bis zum 
Gramm-Maßstab möglich wurde und eine seltene Tochtersubstanz von Ibuprofen erstmals effizient 
gereinigt werden konnte. 
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1 GENERAL PART 
1.1 INTRODUCTION 
1.1.1 XENOBIOTIC METABOLISM AND DRUG DEVELOPMENT 
The human body is confronted with foreign substances that mainly enter through the gastrointestinal 
tract, the skin and the lung. Within these organs, the cells express numerous enzymes which help to 
mitigate the effects of undesirable or even harmful compounds. In everyday life, we come into 
contact with substances such as food, cosmetic products, aerosols, pesticides and fungicides, but 
people also take drugs for cure or abuse. All these agents perform various actions and interactions 
within the body, which we are just beginning to understand. Xenobiotics can be structurally altered 
by enzymes such as cytochromes P450 (CYP) or flavin-containing monooxygenases (FMO). These 
reactions are considered to be the first step in drug detoxification of the liver (but also to some 
extent in other tissues), the so called phase I in drug-metabolism. In the second phase, better soluble 
conjugates of the xenobiotics are produced; reactions that are catalyzed by enzymes in the liver, such 
as glucuronyl-, sulfo- or glutathione-S-transferases (UGT, SULT and GST, respectively) (Figure 1). The 
enzymes of phase I and phase II work together and 
undergo feedforward or feedback control. 
Recently, there has been evidence for the 
existence of drug-metabolizing enzymes in 
microvesicles formed from hepatocytes, which 
may act as extracellular “drug metabolizers”5. 
Another important aspect of drug metabolism is 
the way foreign substances enter the organism 
and the cells. Transporter families involved in 
toxification and detoxification processes have 
been identified, for example ATP-binding cassette- 
(ABC-) transporters or solute carriers (SLC). 
Moreover, xenobiotics influence gene 
transcription through transcription factors, e.g. 
the pregnane X receptor. The complex systems 
mentioned above, which also interact, have 
evolved in organisms to cope with external 
chemicals, and cytochrome P450 (CYP) systems were among the first ones to be discovered. The 
remarkable interindividual differences in drug response are at least partly due to polymorphisms in 
the CYP genes.   
Moreover, most drug metabolism mechanisms are immature at birth and develop during the first 
years of life. These differences in the equipment with enzymes of phase I and phase II of drug 
metabolism are not sufficiently considered when drugs have to be prescribed to pregnant women or 
newborns. 
FIGURE 1: XENOBIOTIC METABOLISM BY CYPS AND UGTS IN THE 
HUMAN LIVER. SCHEMATIC VIEW OF THE FUNCTIONALIZATIONS 
IN PHASE I AND PHASEII OF DRUG METABOLISM. 
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A very small percentage of the candidates for a new drug makes it through the developmental 
process and finally gets approved by the regulatory departments. Immense amounts of money are 
spent for drug discovery; in 2001, the average cost for developing a drug were estimated to lie about 
US $804 million1. During the developmental process, there are several points where a compound can 
fail. The main reasons assumed for attrition can be seen in Figure 2. Four of the reasons shown are 
related to the activity of drug-
metabolizing enzymes. Adverse 
drug effects have several possible 
causes; among them are toxic 
metabolites of the drug. In 2006, 
the American Food and Drug 
Administration (FDA) released a 
guideline for Metabolites in Safety 
Testing (MIST). Drug metabolites, 
which are found in certain 
percentages, must be animal tested 
to be approved. That is why those 
metabolites are to be identified and 
produced in relevant amounts for 
investigation. About 75% of the current drugs are metabolized by human CYP enzymes, and of these, 
about half of the relevant metabolism is catalyzed by human CYP3A enzymes which thus are very 
important both for testing the drug and for the production of such metabolites2. 
 
1.1.2 CYTOCHROMES P450 – PROTEINS AND REACTIONS 
CYPs comprise a superfamily of heme-thiolate containing membrane-bound monooxygenases. More 
than 10.000 CYP genes have been identified to date, the majority of them in bacteria and plants. The 
57 members identified in humans (Nomenclature is described in detail in 2.1 Neunzig et al., 2011) are 
able to perform various reactions as hydrocarbon hydroxylations, demethylations, dehydrogenations, 
N-, S- and O-dealkylations, oxidative deaminations and many more. An excellent overview can be 
found in the following review articles6, 7. However, most human CYPs catalyze the scission of 
molecular oxygen while they introduce one atom into the substrate and reduce the second one to 
water (Figure 3 B). The electrons that are needed in the heme centre to reduce the iron are delivered 
via redox partner proteins such as the NADP(H)-Cytochrome P450 reductase (CPR) in the case of 
microsomal CYPs (resident in the ER membrane, see Figure 3A) and via Adrenodoxin (Adx) and its 
reductase (AdR) in the case of mitochondrial CYP systems. The latter ones are playing crucial roles in 
steroid hormone, Vitamin D and bile acid biosynthetic pathways. For the metabolism of drugs and 
other xenobiotics, CYPs in the ER membrane of liver cells are the most important ones, but they are 
also active in other tissues such as lung or intestine. In other organisms there are other reductases 
which in most cases show high sequence similarity in the regions considered to be essential for the 
reaction (FAD and FMN binding regions for example). Even in plants, where the number of CYPs often 
exceeds the one found in animals, there are only found up to three different reductases per species.  
The reaction cycle with the insertion of one molecule oxygen from molecular oxygen to the substrate 
and the release of water is shown in Figure 3B. 
FIGURE 2: REASONS FOR DRUG ATTRITION DURING DEVELOPMENT. FROM1, 2. 
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FIGURE 3: A: CYTOCHROME P450 SYSTEM IN ENDOPLASMIC RETICULUM (ER) MEMBRANE (ON THE LEFT) WITH MICROSOMAL P450 (CYP 
WITH HEME) AND REDUCTASE (CPR WITH FAD AND FMN) AND B: (ON THE RICHT) GENERAL REACTION MECHANISM FOR CYP CATALYZED 
OXIDATIONS (
2
). 
The electric state of the heme-iron at the active site of the CYP changes from low-spin to high-spin 
with substrate binding. This induces the transition of an electron from NADPH to the iron via the 
reductase to reduce the ferric iron to the ferrous form. Subsequently, molecular oxygen binds to the 
heme, followed by a second electron being transferred from the reductase and reducing the 
dioxygen adduct to a negatively charged peroxo group (bottom of the cycle). This is a rather unstable 
intermediate which is then protonated twice followed by water release. After the hydroxylation of 
the substrate, the product is released and water binds again to the distal position of the heme in the 
active site. However, this cycle is only a simplified version of the steps that are actually more 
dynamic2 .   
For optimal catalysis, many human CYPs require the ubiquitous electron transport hemoprotein 
cytochrome b5
8. 
Most CYPs have a size of about 500 AA and a molecular weight of approximately 55 kDa. The first 
crystallized structure was that of the bacterial P450cam9, which is still widely used in biotechnology 
today. Despite less than 20% of gene identity across the superfamilies, all CYPs share a common 
structure10. However, the transition of results from the crystallization of bacterial CYPs to 
mammalian ones is questionable, as these are cytosolic and the human CYPs are membrane-bound. 
The heme iron is principally bound to a conserved cysteine, which is its fifth ligand and part of the 
highly conserved sequence motif Phe-X-X-Gly-Arg-X-Cys-X-Gly. The common method for the 
quantification and identification of CYPs is the CO-spectrum, based on the shift in absorption of the 
heme from 420 nm to 450 nm when CO binds. Therefore, the enzymes are called P450. Other heme 
proteins do not behave this way as their fifth ligand is usually a histidine.  
In general, the structures of CYP families share between 10-30 % identity10, with some important 
elements that are found throughout all members such as the F/G-segment which forms the roof of 
the substrate binding pocket and thus controls the access to the active site together with the B/C-
loop and the K- and the I-helices carrying signal-recognition sites (SRS)11, 12. A proline-rich region 
seems to be very important for correct folding of membrane bound CYPs13. Relating function to 
structure is still very difficult, though14. A database called Cytochrome P450 Engineering Database 
(CYPED) was established to integrate structure and function knowledge of all known CYPs15, this 
could help to improve our understanding in the future.  
A B 
General Part – Introduction 
 
6 
 
CYP mRNAs start to be translated in the cytosol as precursors containing N-terminal localization 
signals, with the signal recognition particle (SRP) delegating them to the receptor Sec61 in the target 
membrane16 where translation is completed. However, this general view has to be refined, as there 
are examples of the so called bimodal or chimeric targeting17, 18. The respective signals can be used 
for targeting these to different subcellular destinations, depending on phosphorylations of nearby 
regions19. Figure 4 shows the current view of the orientation of CYP2C9 in the membrane with the 
substrate ibuprofen entering through accession channels from within the phospholipid bilayer. 
The F/G-loop and A’-helix in this model 
are situated within the membrane. This 
is an example to illustrate the 
orientation of an active CYP in the 
membrane.  
Cytochromes P450 do not only 
metabolize foreign compounds, they 
are also essential for steroid, vitamin D 
and bile acid biosynthesis. Among their 
substrates there are also substances 
which become toxic or carcinogenic 
(like benzo(a)pyrene) by the reactions 
catalyzed. Other compounds (pro-
drugs) are not active before they are 
converted by a CYP. Inhibition of CYP 
activity by xenobiotics, such as for 
example the inhibition of CYP3A4 by 
furanocoumarins from grapefruit juice, 
also play a significant role in drug 
efficacy. The subfamily CYP3A 
metabolizes about half of the drugs 
prescribed today2. Table 1 shows the most important xenobiotic and endogenous substrates and the 
respective CYP classes which metabolize them. 
TABLE 1: HUMAN CYP CLASSES WITH RESPECTIVE SUBSTRATE CLASSES, FROM 2. 
 
 
ibuprofen 
3-hydroxyibuprofen 
CYP2C9 
FIGURE 4: CYP2C9 WITH PROPOSAL OF ACCESS/EGRESS OF IBUPROFEN IN AN 
EQUILIBRATED DIOLEYOLPALMITOYL-PHOSPHATIDYLCHOLINE (DOPC) MEM-
BRANE. THE CPR BINDING REGIONS ARE ACCESSIBLE TO WATER IN THIS MODEL. 
PARTS THAT ARE NOT EXPOSED TO WATER ARE SHOWN IN VIOLET, THE HEME IS 
SHOWN IN RED AND PARTS EXPOSED TO WATER ARE BLUE. TAKEN FROM
4
 WITH 
MINOR MODIFICATIONS. 
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It has to be added that CYP3A enzymes play relevant roles in the hydroxylation of the steroid 
hormones testosterone and DHEA (see next paragraph). 
 
1.1.3. THE SUBFAMILY CYP3A 
Human CYP3A enzymes display wide substrate specificities and are essential for both endogenous 
processes and for drug metabolism. CYP3A is the only CYP3 subfamily and the related gene-cluster is 
located on chromosome 7q21-q22.1. It comprises 3 pseudogenes, at least three active enzymes 
(CYP3A-4, -5 and -7) at the current state of knowledge and one recently discovered one (CYP3A43)20 
which is considered to possibly play a role in prostate and colorectal cancer21. The CYP3A isoforms 
are expressed in a polymorphic manner and are dependent on developmental stage, ethnicity and 
tissue22. Furthermore, there is evidence for different linkage disequilibriums in the expressions of 
CYP3A5 and CYP3A7. The transcriptional control of the three CYP3A enzymes is isoform specific, as 
their mRNAs are found tissue-specifically. CYP3A4 is predominantly found in the liver and the 
intestine, while it is not abundant in the prostate and adrenal gland and only CYP3A5 is found in the 
kidney23. 
CYP3A4 evidently is the most relevant isoform in man and was discovered in the 1980s as a 
glucocorticoid-inducible form of P45024. This CYP isoform is the most abundant in the liver and small-
intestine and is furthermore considered to be the one that is most involved in drug-drug interactions.  
There is no null allele for CYP3A4 and the ~30 SNPs occur in less than 5 % of the population and then 
mostly heterozygously25. It has the broadest catalytic selectivity of any human CYP: CYP3A4 
metabolizes various reactions as the oxidation of nifedipine (drug against hypertension and angina 
pectoris), the C3-hydroxylation of acetaminophen (analgesic), the demethylation and C14-
hydroxylation of clarithromycin (antibiotic), the C2-hydroxylation of imipramine (antidepressant), the 
dehydrogenation of raloxifene (estrogen-receptor modulator) and numerous more. This list 
illustrates the broad range of medicinal substrates. Endogenous substrates are predominantly sterols 
such as DHEA, pregnenolone, progesterone and testosterone, where C16α-and C6β-hydroxylations 
dominate, but also C2β-, C4β-26, 7β-, C15α- and -β- or C21-hydroxylations have been reported27.  
The list of the polymorphic forms of CYP3A4 (as well as those of all other human  
CYPs) is frequently updated on the site of Sarah Sim at the Karolinska Institute of Sweden[1]. While 
many mutations cause a decrease in enzyme activity, there is only one variant with increased activity, 
which is CYP3A4*18 causing the AA change L293P. Further details on this topic can be read in the 
publication 2.4: Neunzig et al., 2012b. There are also other variations that affect the promoter 
regions as CYP3A4*1C28. 
The first crystal structures of CYP3A4 were published in 2004, where the crystals had either 
metyrapone, progesterone or no ligand bound to different regions. Admittedly, the region where 
progesterone was found to bind in this study was too distant from the active site for catalysis to 
occur and the unbound structure did not differ much from the ligand-bound one12. A more recent 
report of crystallized CYP3A4 structures with erythromycin or ketoconazole shows the expected 
differences in the 3D-structure when ligands are bound or not29. Its multiple ligand binding sites and 
homo- and heterotrophic cooperativity towards certain substrates are unique among human 
microsomal CYPs. CYP3A4 has a broad substrate specificity that ranges from small molecules to 
about 10-fold bigger ones with masses up to 1201 Mr like cyclosporine A
27, 30. It can be influenced in 
various manners as shown in Figure 5.  
                                                                 
1
 www.cypalleles.ki.se 
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FIGURE 5: SRUCTURE MODEL OF HUMAN CYP3A4 WITH DIFFERENT EFFECTORS. THE SUBSTRATE BINDING POCKET DOES OF COURSE NOT 
OUTSTAND AS FIGURED HERE FOR BETTER OVERVIEW. IN FACT, THERE ARE MULTIPLE BINDING SITES AS DESCRIBED ABOVE. MODIFICATED 
FROM
31
. 
For CYP3A4, multiple ligand binding has been suggested and shown once for ketoconazole 
(inhibitor)29, but this was only another indication for the theory proposed earlier, as the authors state 
that this could be due to the crystallization process. If this proves to be true, a substrate can 
theoretically be metabolized and bind to an effector site simultaneously.  
Regarding the regulation of CYP3A4 expression, there has been evidence for several transcription 
factors and nuclear receptors involved such as the pregnane X receptor, vitamin D receptor or 
retinoid X receptor α32-34, but also microRNAs regulating on posttranscriptional level35. Some 
structural features were proposed to be exclusively found in CYP3A enzymes, as the phenylalanine-
cluster above the active site, which may be responsible for the different way they perform their 
reactions when compared to other CYP-catalyzed reactions in vitro like CYP2C9 or CYP2D636.   
The second CYP3A form that was characterized in the 1990s37 was CYP3A5, an enzyme which is 
expressed in a highly polymorphic manner. The CYP3A5*1 allele (frequency dependent on ethnicity 
ranging from 17%-50%) leads to an active form of CYP3A5, that e.g. improves overall tacrolimus 
clearance, when compared to carriers of the CYP3A5*3 allele38.  CYP3A5*3 encodes a splice-mutant 
form and results in the termination of translation. About 85 % of Caucasians bear CYP3A5*3 and thus 
have no functional CYP3A5 protein28.  
CYP3A7 is the most abundant CYP isoform in the embryonic liver39 and plays a crucial role in the 
DHEA metabolism which is indirectly linked to such basic processes as the growth of nerves and 
blood vessels. For drug detoxification, which should not be necessary in the fetus to the same extent 
as in the adult, not much data exists. One example for the difference between CYP3A4 and CYP3A7 
activity is the inability of CYP3A7 to metabolize cisapride – leading to severe side-effects40. CYP3A7 
can be found in about one out of ten adults due to a polymorphism in the promoter region 
(CYP3A7*1). About 60 % of adult CYP3A7 expressors carry the CYP3A7*2 polymorphism, which leads 
to improved estrone-, DHEA- and testosterone- hydroxylation41, 42.  The role of CYP3A7 expression in 
adults in several forms of cancer has also been discussed43, 44.  
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1.1.4 FUNCTIONAL EXPRESSION OF HUMAN CYP ENZYMES IN FISSION YEAST 
For the characterization of their activities and interactions, but also for biotechnological purposes, it 
is much easier to produce CYP enzymes with microbial organisms than to extract them from human 
tissues or work with mammalian cells. The functional expression of human CYPs in different microbes 
for the production of diclofenac was compared in our publication [2.2: Drăgan et al., 2011]. Next to 
baker’s yeast (Schizosaccharomyces cerevisiae), fission yeast (Schizosaccharomyces pombe) is the 
second best studied yeast in molecular biology. The name pombe comes from the Swahili word for 
beer and the yeast was first isolated in 1893 by Lindner from African millet beer. Figure 6 shows 
fission yeast cells from electron microscopy. The cells have a size between 7-14 µm in length and 3-4 
µm in width.  They proliferate in either a mitotic or meiotic way by fission and two mating types are 
known. Depending on the environmental conditions (nutrition, space, temperature, oxygen etc.) they 
adapt their reproductive strategy from vegetative to meiotic 
growth by developing four haploid spores for sexual 
differentiation and exchange.  This unicellular organism is in some 
aspects much closer to higher eukaryotic cells than baker’s yeast, 
which tends to hypermannosylate recombinantly expressed 
proteins. Fission yeasts membrane structure45, cell cycle control, 
posttranslational modifications (contains e.g. a galactosyl-
transferase46, 47), splicing machinery48 and chromosome structure 
and function (large and complex centromeres,  miRNA regulation, 
heterochromatin[ 2 ]) resemble much more those found in 
mammalian cells than those of baker’s yeast49, 50. Its genome has 
been entirely sequenced in 200251 and bears more introns (about 
5000 compared to ~250) than the genome of Saccharomyces 
cerevisiae, thus hinting on the phylogenetic differences.  In many 
cases, fission yeast seems to be better suited for the expression 
of recombinant mammalian proteins than baker’s yeast52. Much 
of what we know about the control of the mammalian cell cycle has first been studied in fission 
yeast.  Thanks to decades of research, an enormous quantity of vectors and other tools for genetic 
manipulation for investigational or biotechnological purposes are available. Comparatively short 
generation times (about 3 hours for wild types) and the GRAS (generally regarded as safe) status 
grant a good basis for its use as a host for human cytochromes P450 systems. Fission yeast has only 
two endogenous CYPs which are involved in ergosterol biosynthesis (CYP51: sterol-14α-demethylase 
and CYP61: sterol Δ22-desaturase), thus providing a low background for P450 activities. The aim of 
this study was to establish stable strains which functionally express human CYP3As and which 
furthermore can be used in whole-cell transformations of potential substrates, what has been shown 
for some comparable cases, as for CYP11B1/CYP11B253, CYP17 and CYP2154, CYP2B655, CYP2D656 and 
CYP4Z157, before. The upscaling of such whole-cell transformation systems was part of this work and 
is discussed in 2.2: Drăgan et al., 2011.  
 
 
 
                                                                 
2
 http://www-bcf.usc.edu/~forsburg 
FIGURE 6: S. POMBE CELLS, SCANNING 
ELECTRON MICROGRAPH OF FISSION YEAST 
(SCHIZOSACCHAROMYCES POMBE). 
ILLUSTRATION: JÜRGEN BERGER/MAX 
PLANCK INSTITUTE FOR DEVELOPMENTAL 
BIOLOGYPICTURES.  
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1.2 AIMS AND SCOPE 
Drug metabolism by human CYPs has been in the focus of the pharmaceutical research for decades. It 
is becoming more and more state of the art to test possible metabolites during the test phase of a 
new compound. Enzyme preparations and microsomal preparations from recombinant bacteria, 
insect cells or yeasts are used for those kinds of tests. This has the advantage of accessibility for a 
broad range of substrates – but for production of bigger amounts in the gram scale these systems are 
not useful (see Table 3 in 2.2: Drăgan et al., 2011). The fission yeast system has previously been 
shown to be useful for the production of small amounts of CYP11B1, CYP2B6 and CYP2D6 dependent 
metabolites. As CYP3A and CYP2C9 today are considered to be the most important drug metabolizing 
CYPs, the focus of this work lies on whole-cell conversions with these enzymes. There are two 
commonly used analgesic drugs which are converted by CYP2C9: diclofenac and ibuprofen. The 
chemical synthesis of their metabolites is both difficult and expensive (4-hydroxy-diclofenac) or has 
not been described to date (3-hydroxy-ibuprofen). The development of convenient and efficient 
whole-cell biocatalytic systems for the production of specific metabolites is the global goal of this 
work. Fission yeast strains expressing the respective CYPs and partially also the P450 reductase either 
already existed or were newly cloned. Several approaches for improvement of the overall 
biotransformatic activities are followed contemporaneously on three levels: On the first level, 
conditions during conversion as the substrate concentration, media (glucose and pH), temperature, 
etc. should be optimized. On the level of the P450 system, the bricks should be varied (as testing 
several reaction partners) and third, the CYPs themselves could be improved in their ability to 
convert the respective substrates, eventually by using existing polymorphisms which are known to 
improve the enzymes’ activity towards certain substrates.   
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3    DISCUSSION AND CONCLUSIONS  
3.1 CLINICAL RELEVANCE 
The plasma level of a drug at its target location determines its activity and side-effects and depends 
on its pharmacokinetics. The abbreviation LADME stands for liberation, absorption, distribution, 
metabolism and excretion and summarizes the involved processes. Metabolism or biotransformation 
of the drug means it is (in most cases irreversibly) transformed to one or more daughter metabolites 
to facilitate excretion. This is where Cytochrome P450 enzymes (CYPs) play a key role. Estimations 
assign CYPs to be involved in at least three quarters of drug metabolism in the liver and 95 % of these 
are assigned to five liver CYPs (1A2, 2C9, 2C19, 2D6, 3A4)2. Interindividual differences in drug 
response are not surprising if one considers the various processes involved in pharmacokinetics 
described above. A considerable part of them can be ascribed to pharmacogenetics: polymorphisms 
in DMEs, especially in CYPs61 can strongly influence the plasma levels of a drug through elevation or 
decrease of the respective CYPs activity towards the substance in question. This is a matter of point-
mutations, missense mutations, insertions, deletions but also of copy number variations or 
mutations influencing gene expression, as for example polymorphisms in the promoter or any other 
regulatory region of the gene. The expression polymorphism is used when such an alteration occurs 
in more than 1% of the examined population. The best studied examples for polymorphisms in CYPs 
are in CYP2A6, CYP2B6, CYP2C9, CYP2C19 and CYP2D6. For CYP1A2 and CYP3A4, however, 
interindividual variety is considerable, yet molecular mechanisms have not been elucidated so far. In 
CYP3A4, known polymorphisms are numerous62-65, but their influence on overall drug-clearance is 
not yet clear31. Both other 3A-isoforms have been found to be polymorphically expressed as 
described in the introductory part and in the introduction of the respective publications58, 60. The 
influence of the polymorphism on drug metabolism in specific cases can be investigated as follows: 
The first way is the direct association of the polymorphism and the plasma level of the administered 
drug in the patient via blood-sampling and/or urine samples and subsequent HPLC analysis of the 
metabolites66. The second possibility, which should logically be the state of the art in drug 
development, is the testing and comparison of the specific activities of the wt-genes and the 
polymorphic forms with isolated or recombinantly expressed enzymes67. Several systems are 
available, with the fission yeast system developed during this work being an economic and efficient 
alternative to the previously existing methods. The two naturally occurring polymorphisms 
CYP3A4*18 and CYP3A7*2 were introduced into the wt enzymes and expressed in fission yeast cells. 
A miniaturized whole-cell system with the yeasts grown in minimal medium, harvested and 
resuspended in reaction buffer at a variable pH for testing of different substance groups was 
developed. During the author´s diploma thesis, the basis for the assay system was created with the 
cloning of the CYP3A7 and CYP3A7*2 expressing strains INA1 and INA2. It was shown that a 
microtiter plate based system using these strains can be used for testing the substrate specificities 
and differences in activity between the wt and polymorphic enzymes and reflects the proportional 
activities gained with other systems. Expensive cofactors as are required for in vitro tests with 
enzymes expressed in baculovirus infected insect cells or isolated from bacteria are not needed, as 
the living fission yeast itself supplies the enzymes with reduction equivalents (from NADPH) via the 
coexpressed CPR. Fission yeast strains expressing several of the other main human drug metabolizing 
CYPs (CYP2B6, 2C9, 2C19, 2D6, and 3A4, resp.) had already been cloned by Călin Aurel Drăgan. In the 
present work, additional strains for the expression of CYP3A5 and CYP3A4*18 were created, and the 
activity data gained with these new strains reflect the ratios between wt and polymorphic enzymes 
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in vivo (see 2.3: Neunzig et al., 2012 ABAB, Figures 3 and 4). However, to efficient use this system, a 
laboratory for yeast-cell culture and subsequent HPLC analysis is required. The investigation of S. 
pombe expressing human CYPs and CPR as a host for functional microsome preparation was carried 
out with the help of Mrs. Sarah Fitsch who was mentored by the author. Reliable results were 
obtained for CYP3A4, CYP3A4*18, CYP3A5, CYP3A7, CYP3A7*2, CYP2C9 and CYP2D6 expressing 
fission yeast strains (unpublished results). The required cofactors and the regenerating system 
consisting of G-6-P and G-6-P DH could be reduced by a factor of four and the relative activities with 
standard substrates resembled those obtained with Supersomes™ (data not shown). The microsomal 
preparations were cryostable at -80 °C for at least 2 months without a significant loss of activity. 
Further experiments with this system are required to confirm it to be an economic alternative to 
existing products (Bactosomes, Supersomes or Cerosomes) for rapid screening of drug candidates in 
labs which need not be qualified for work with recombinant organisms. 
 
Gene expression can not only be influenced by polymorphisms, but also by other mechanisms such 
as the development of cancer and ongoing changes in transcription. Hepatocellular cancer (HCC) is a 
malignant form which often develops after infection with hepatitis B virus or upon liver exposure to 
toxic substances such as alcohol or aflatoxin B and it is one of the major causes of death worldwide. 
The investigation of the gene patterns that are expressed in HCC cells is one of the key steps in 
understanding the disease. One such gene that was identified to be highly expressed in HCC is 
CYP3A768, 69. During cancerogenesis, cells undergo a dedifferentiation which implicates the 
expression of genes associated with early cell states. It was unclear at the beginning of this work 
whether CYP3A7 is expressed in HCC upon dedifferentiation; in other words, whether it is a 
secondary effect or whether it plays an active role in the generation of the cancer. In the latter case, 
specific inhibitors of CYP3A7 might be potential anti-cancer drugs. Most chemotherapeutics are 
metabolized by CYPs especially by CYP3A enzymes; this is (at least for CYP3A4) tested in most cases 
during the drug development process. Consequently, the individual equipment with CYPs should be 
considered in both the development and the administration of cytostatic drugs. Personalized cancer 
therapy based on transporter-enzyme interplay for CYP3A enzymes has been proposed recently70. 
One example for such a substrate is the anti-cancer drug sorafenib: its biotransformation by CYP3A4 
to an N-oxide is known71. In contrast, CYP3A7 dependent metabolism was never tested, although it is 
important for the drugs’ efficacy at its site of action. In one scenario, it would inactivate the drug by 
biotransformation and in a second one, it could even convert it to a toxic metabolite. In the first 
publication of this work [see: Neunzig et al., 2011 (BBA PP), Figure 4], it was demonstrated that 
CYP3A7 does not metabolize sorafenib and, thus, does not influence its activity in HCC. CYP3A7 is 
expressed in many cancerous tissues44 -very recently, its induction by the important tumor 
suppressor protein p53 has been demonstrated72.  It is still not clear, whether CYP3A7 expression is 
involved in cancerogenesis or if it is a secondary effect of cancer development but, still, its increased 
expression in the cancer tissue has to be considered in drug development. The potential of human 
enzymes to functionalize the drug candidates is one of the key steps in understanding a drug’s mode 
of action in the human body. Very recently, the involvement of CYP3A7 in the oxidation of 
haloperidol metabolites in human placenta was suggested73. This is an example, where the novel 
system for whole-cell biotransformation with CYP3A7 presented in this work could have been used 
for more specific testing. Furthermore, substrate specificities between CYP3A4, CYP3A5, and CYP3A7, 
resp., can be easily distinguished with the respective analytical background at hand.  
Cytostatic drugs often have severe side-effects and can thus be very harmful to the patient’s healthy 
body cells irrespective of their effect on the cancer cells. As some CYPs are specifically expressed in 
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cancerous tissues, they could act as targets for drugs that are activated by a CYP specific metabolism, 
a so-called prodrug strategy. Most pharmaceutically active compounds are inactivated by 
metabolisation, but some, like cyclophosphamide, are activated to cytotoxic agents. If CYP expression 
is specific to cancer cells, as for example with CYP3A7 which only is expressed in a small number of 
adult livers due to a promoter polymorphism CYP3A7*1C, but which is found in every hepatocellular 
cancer, the drug would only be activated at the target location. In order to screen for drug 
candidates, systems like the fission yeast based one described here (or the microsomes derived from 
it) are useful tools for preselection.  
Another strategy to achieve lower doses of toxic drugs in cancer therapy (with the aim of reducing 
side effects) would be the specific inhibition of the inactivating CYPs. A CYP-specific inhibitor test 
system with fission yeast as a host was published in 200654. However, the strain construction for the 
CYP17 and CYP21 expressing yeast used there was different from the one applied in this study. The 
parental strain MB175 was transformed with the human CYP cDNAs without the additional 
expression of human CPR. When developing the CYP3A7 system, this parental strain was also 
transformed with expression plasmids for both CYP3A7 and CPR; however, the resulting strain grew 
significantly slower and had a much lower biotransformatic activity towards testosterone and DHEA 
than the MB163 derived strains (data not shown). Thus, the CYP3A7 system based on MB163/CAD62 
was chosen for inhibitor testing and the determination of IC50 values for econazole and miconazole 
were determined. These two compounds were chosen because they are typical CYP inhibitors. As 
part of a pilot study, several furanocoumarins (e.g. 7-hydroxycumarin and umbelliferone) were 
tested for their inhibitory potential on CYP3A7 (unpublished results). None of the selected 
compounds showed an inhibition of CYP3A7 activity. In conclusion, the inhibitor test system 
established in this work for both a luminogenic substrate [see: Neunzig et al., 2011 (BBA PP), Figure 
3] and DHEA (data not shown) is a valuable tool for determining IC50 values of potential CYP3A7 
inhibitors and for distinguishing between CYP3A7, CYP3A5, and CYP3A4 specificities, respectively.  
3.2 BIOTECHNOLOGICAL RELEVANCE 
The demand for metabolites of DMEs as reference substances is growing with the increase of 
pharmacological research. The production of CYP specific metabolites is very expensive in some 
cases, as they can be stereo- and regio-specifically modificated. Chemical syntheses implicate the use 
of toxic chemicals and solvents and also are limited. Not every metabolite can be produced that way. 
Especially stereospecific reactions (as certain α- or β-hydroxylations) are hard to carry out or even 
impossible by chemical means. The advantages of a production with recombinant microorganisms 
are obvious, as the process is faster in most cases, once established easily reproducible and more 
environment-friendly. The amounts produced as reference substances of high purity lie within the 
mg range – however, quality management guidelines such as good laboratory practice (GLP) and 
good manufacturing practice (GMP) standards require periodic calibration and standard curves for 
HPLC detection. Therefore, the reference substances are needed at regular intervals. Moreover, the 
American food and drug association (FDA) has released a guideline in 2008 proposing that every 
metabolite that is produced in more than 10 % of the initial drug concentration has to be safety 
tested. This means its toxicity has to be evaluated in animal tests[3]. For these tests, up to gram 
amounts are needed. This underlines the necessity for adequate production methods. A wide spread 
method for the production of smaller amounts of drug metabolites are the commercially available in 
vitro systems (microsomes from recombinant baker’s yeast or baculovirus infected SF1-cells). The 
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Discussion, Conclusions and Outlook 
 
79 
 
disadvantages of these systems are mainly the costs for the microsomes themselves and for the 
cofactor NADPH. An upscaling of these systems is theoretically feasible but very expensive. Whole-
cell biotransformations, where a host organism is transformed with the respective enzymes or where 
a microbe is found to produce the requested metabolites endogenously, are much more efficient. In 
2006, there still was not much data on the biotechnological use of human CYPs 7. As discussed in the 
introduction, fission yeast has now proven to be a suitable host for the expression of human CYPs. 
Although we could even produce isotope-labeled sterol products with CY3A4 (data not shown), the 
first successful production of 40 mg of a designer drug metabolite was carried out in 2007 with a 
CYP2D6 expressing strain (without CPR coexpression, however)56, and prior to this work more than 
mg amounts had never been produced using this approach. The upscaling of the fission yeast based 
biotransformations with human CYP2C9 that were originally carried out either in 10 mL of EMM 
medium in 250 mL Erlenmeyer flasks, in the 1 mL scale in Eppendorf tubes or in a 500 mL fermenter, 
was accomplished by switching to 1 L biotransformation culture in 2 L Erlenmeyer flasks and an 
optimized culture technique. From 1 mM diclofenac, about 80-90% were metabolized to the main 
metabolite in the small scales (1 to 10 mL) within 24 hours (unpublished results). The transformation 
activity of the CYP2C9 expressing strain showed a linear increase in product over the time. When 
cells were cultivated in the fermenter prior to substrate addition, however, the activity did not reach 
20% of 1 mM within the first 2 days (unpublished results). The growth phase of the cells obviously 
influences their overall biotransformation activity. For further characterization of that phenomenon, 
various cell culture techniques were applied for the CYP2C9 dependent process and the optimal 
point for the induction by lack of thiamine was determined and applied. The approach in the 
fermenter was dropped, as the different medium and adjustment of the pH with NaOH do not allow 
the ideal growth strategy as figured out in flasks. Therefore, we adapted the culture techniques from 
the small scale conversions together with the best conversion conditions (concerning oxygen, 
glucose, pH and cell density) to the 1 L scale. Several systems for the bioproduction of CYP 
dependent metabolites have been discussed in publication 2.2: Drăgan et al., 2011 with respect to 
the exemplary production of 4'-hydroxy diclofenac. Although the different systems, as Actinoplanes, 
Epicoccus or E. coli have their individual specialties and restrictions and are therefore difficult to 
compare, the overall space-time yield was the 
highest with the optimized fission yeast batch 
culture in the 1 L scale (production of 2.8 g with 
6 biotransformation runs) [see 2.2.: Drăgan et 
al., 2011 (ABAB), Table 3]. Furthermore, we 
were able to very rapidly produce 44 mg of the 
commercially not available 3-hydroxyibuprofen 
(see publication 2.3: Neunzig et al., 2012a) in 
the same system. Ibuprofen was developed in 
1969 and is widely applied as analgesic.  24 
hours after the intake, approximately 60 % of 
the doses are found in urine as 2-hydroxy, 
carboxy- and 3-hydroxyibuprofen (Figure 7). The 
chemical synthesis of 3-hydroxyibuprofen is very 
difficult and the only publication on this issue74 
reported a yield of 0.5 mg. A simple method of 
purification was developed using a pre-
purification with TLC plates and subsequent 
FIGURE 7: IBUPROFEN STRUCTURE AND ITS METABOLITES. 1-
HYDROXYIBUPROFEN (1-OH-IBU) IS ONLY FOUND IN TRACES IN 
URINE, THE OTHER METABOLITES ARE FOUND IN VARIABLE 
AMOUNTS; 3-OH-IBU IS CONVERTED TO CARBOXYIBUPROFEN. *NMR 
STRUCTURE FIRST SHOWN IN 2007 
3
.  
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purification by fractionation from RP-HPLC [see 2.3.: Neunzig et al., 2012a (JOB), Figures 2 and 4]. 
NMR analysis confirmed its identity and was consistent with the NMR data from Chang 74 but not 
with the contradictory data from an isolation from urine75 [see 2.3.: Neunzig et al., 2012a (JOB), 
Figure 5]. The latter data did not show any hydroxylation of a methyl group and thus appears to be 
misleading. In conclusion, a very efficient process for the large-scale production of a stereospecific 
hydroxylated CYP dependent metabolite with recombinant fission yeast was developed. 
After adjusting the biotransformation conditions for a maximal metabolite production, in a second 
step, the publications 2.4: Neunzig et al., 2012b and 2.5: Neunzig et al., 2013 (submitted) provide 
data on the elevation of CYP-dependent activities in the fission yeast whole-cell system by (I) 
molecular engineering of the CYP3A enzymes and (II) coexpression of different redox partners, 
respectively. The CYP3A4 system with human CPR was already available in the lab; now, for the first 
time, CYP3A7 and CYP3A5 were functionally expressed together with human CPR, fission yeast ccr1, 
or a plant reductase from Ammi majus (AmCPR), respectively. Natural occurring polymorphisms are 
sometimes found to increase the intrinsic activity of a CYP towards certain substrates. Two such 
polymorphisms are CYP3A4*18 (L293P) and CYP3A7*2 (T409R). We used this knowledge to generate 
expressor strains for all combinations of these mutations with all human CYP3A isoforms and tested 
these with different substrates. Interestingly, for six out of seven newly created mutants, activity for 
at least one of the tested substrates was elevated.  The results were surprising in some aspects, as 
for example the introduction of L293P to CYP3A4 increased the 6β-hydroxylation activity of 
testosterone but decreased the 16-hydroxylation activity towards the closely related substrate DHEA. 
This indicates once more the poor predictability of structure-function relations in human CYP3As, as 
they are very flexible and adapt to the respective substrates and effectors30, 76. The specific activities 
of all three human CYP3A enzymes could be improved up to 400% of the respective wt activity with 
at least one of the tested substrates by applying an economic strategy which combines aspects from 
an evolutionary approach and directed mutagenesis.  
The coexpression of different redox partners yielded 23 new strains. As expected, the 17α-
hydroxylation of progesterone could be significantly enhanced by the coexpression of hCPR, and this 
was also true for the 21-hydroxylation of progesterone by CYP21. For CYP3A dependent 
biotransformation, the human reductase is the only one supporting the tested reactions, while, 
without additionally expressed reductase, the stereospecificity for DHEA hydroxylation shifted. That 
shows the strong dependence of steroid metabolism on the supply with reduction equivalents. 
Regarding the biotechnological point of view, the coexpression of AmCPR improved the 
biotransformation rate of CYP2C9 towards ibuprofen and diclofenac about 150 % and 300 % 
respectively in miniaturized assays. This indicates the “brick strategy” to be as efficient as the 
attempt to elevate the enzymes’ specific activities by introducing polymorphisms. Further bricks to 
test for their ability to improve production rates of CYP dependent metabolites would be cytochrome 
b5 or specific transporters (e.g. ABC-transporters) for the import of substrates and the export of the 
metabolites. Brought together, these two approaches will eventually grant even higher 
biotransformations rates. However, the individual substrates are to be regarded separately in each 
case. In conclusion, this system for the production of human CYPs can be efficiently used for the 
production of most of CYP specific metabolites and for the characterization of enzymatic properties, 
also regarding clinical mutants and polymorphisms.  
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3.3 OUTLOOK 
The five human CYPs which are responsible for the major part of xenobiotic metabolism2 have been 
successfully used for whole-cell biotransformations in the S. pombe-system in our work group. 
Moreover, some of the less well studied isoforms as CYP3A5 and CYP3A7 but also CYP4Z1 could be 
functionally expressed. This is a promising basis for the expression of all other human CYPs involved 
in xenobiotic metabolism as 1A1 (metabolism of aromatic hydrocarbons as benzo(a)pyrene in the 
intestinal mucosa), 2C8 (paclitaxel, sorafenib and others) or 2E1 (ethanol, analgesics). For CYP1A2 
alone, six polymorphisms with decreased enzyme activity in vivo have been reported. With the new 
system, their influence on drug metabolism by the patients in question can be figured out with the 
respective fission yeast strains expressing the polymorphic forms. Many CYPs are assumed to be 
involved in cancerogenesis. Their characterization is essential for a better understanding of these 
processes. Especially the CYPs that do not contribute much to overall drug metabolism are often not 
well studied and have the potential to catalyze rare substances and produce rare metabolites, 
although the search for substrates may be harder. They can also produce harmful metabolites from 
drug candidates, what can be tested for most compounds in a microtiter assay with all human CYPs 
involved in drug metabolism expressed in S. pombe. It is an economical and more thorough 
alternative to currently performed in vitro testing with microsomes from recombinant insect- or 
bacterial cells. Metabolite productions with several intermediates are possible with the whole-cell 
system: with membrane layers or filters separating the cells but not the media and the 
substrate/products, the cells could use the products from the neighbored culture as substrates. 
Another approach would be the combination of different strains in one culture with well-balanced 
proportions. This way, several reactions could theoretically take place one after another with the 
final product being purified at the end of the biotransformations. Of course, product inhibition has to 
be considered and tested therefore. Other drug metabolizing enzymes as UGTs and AKR1 have also 
proven to be functional upon expression in fission yeast and different glucuronides could be 
produced77. A combination of e.g. CYPs (phase I) and UGTs (phase II) expressed in fission yeast is thus 
conceivable with the developed methods. The developed fission yeast system as a valuable and 
economical tool for mimicking human drug metabolism processes has outstanding potential.
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4    ABBREVIATIONS 
AdR Adrenodoxin reductase 
Adx Adrenodoxin 
CPR Cytochrome P450 reductase 
CYP Cytochrome P450 
DME  Drug metabolizing enzyme 
ER Endoplasmatic reticulum 
FDA Food and Drug Administration 
FMO Flavin containing 
monooxygenase 
GST Glutathione-S-transferase 
NAD(P)H Nicotinamide adenine 
dinucleotide (phosphate) 
MIST Metabolites in Safety Testing 
Mr relative Mass 
P450 Cytochrome P450 
SULT sulfo transferase 
UGT uridine diphospho 
glucuronosyltransferase 
wt Wild type 
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